Skip to main content
Erschienen in: Breast Cancer 2/2018

19.01.2018 | Review Article

Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients

verfasst von: Thierry Habyarimana, Mohammed Attaleb, Jean Baptiste Mazarati, Youssef Bakri, Mohammed El Mzibri

Erschienen in: Breast Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

During the last decades, a great interest was given to viral etiology of breast cancer. Indeed, due to recent technical improvements and some encouraging new results, it has been a resurgence of interest in the possibility that a substantial proportion of human breast cancers may be caused by viral infections. High-risk genotypes of human papillomavirus (HPV) have been found in breast cancer cases. In the present study, we aimed to assess the presence of HPV DNA in breast cancer cases from Rwanda and to evaluate the association between HPV infection and clinico-pathological features.

Methods

Therefore, a total of 47 archived formalin-fixed paraffin-embedded biopsies were collected and complete information was recorded. HPV detection and genotyping were done by PCR amplification and DNA sequencing.

Results

Overall, HPV DNA was found in 46.81% of cases, HPV16 being the most prevalent subtype (77.27%) followed by HPV33 (13.64%) and HPV31 (9.09%). Comparison of HPV with clinico-pathological features showed no significant difference between HPV infection and breast localization, histological subtype, clinical stage, tumor grade, and intrinsic molecular subtypes.

Conclusions

These findings provide evidence of high prevalence of high-risk HPV in Rwandese patients with breast cancer and suggest that high-risk HPV infections could be a risk factor associated with human breast cancer development.
Literatur
2.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer base no. 11 [Internet]. Lyon: International Agency for Research on Cancer. 2013. http://globocan.iarc.fr. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer base no. 11 [Internet]. Lyon: International Agency for Research on Cancer. 2013. http://​globocan.​iarc.​fr.
5.
Zurück zum Zitat Stewart BW, Kleihues P. World cancer report. Lyon: IARC Press; 2003. Stewart BW, Kleihues P. World cancer report. Lyon: IARC Press; 2003.
7.
Zurück zum Zitat Wang F, Hou J, Shen Q, Yue Y, Xie F, Wang X, et al. Mouse mammary tumor virus-like virus infection and the risk of human breast cancer: a meta-analysis. Am J Transl Res. 2014;6(3):248–66.PubMedPubMedCentral Wang F, Hou J, Shen Q, Yue Y, Xie F, Wang X, et al. Mouse mammary tumor virus-like virus infection and the risk of human breast cancer: a meta-analysis. Am J Transl Res. 2014;6(3):248–66.PubMedPubMedCentral
10.
Zurück zum Zitat Damin APS, Karam R, Zettler CG, Caleffi M, Alexandre COP. Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat. 2004;84:131–7.CrossRefPubMed Damin APS, Karam R, Zettler CG, Caleffi M, Alexandre COP. Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat. 2004;84:131–7.CrossRefPubMed
12.
Zurück zum Zitat Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci. 1990;87:463–7.CrossRefPubMedPubMedCentral Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci. 1990;87:463–7.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn H-J, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47. https://doi.org/10.1093/annonc/mdr304.CrossRef Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn H-J, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47. https://​doi.​org/​10.​1093/​annonc/​mdr304.CrossRef
19.
Zurück zum Zitat Husnjak K, Grce M, Magdic L, Pavelic K. Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. J Virol Methods 2000;88:125–134.CrossRefPubMed Husnjak K, Grce M, Magdic L, Pavelic K. Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. J Virol Methods 2000;88:125–134.CrossRefPubMed
21.
Zurück zum Zitat Corbex M, Bouzbid S, Traverse-Glehen A, Aouras H, McKay-Chopin S, Carreira C, et al. Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors. PLoS One. 2014;9(12):e114559. https://doi.org/10.1371/journal.pone.0114559.CrossRef Corbex M, Bouzbid S, Traverse-Glehen A, Aouras H, McKay-Chopin S, Carreira C, et al. Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors. PLoS One. 2014;9(12):e114559. https://​doi.​org/​10.​1371/​journal.​pone.​0114559.CrossRef
23.
Zurück zum Zitat El-shinawi M, Mohamed HT, Abdel-Fattah HH, Ibrahim SAA, El-Halawany MS, Nouh MA, et al. Inflammatory and non-inflammatory breast cancer: a potential role for detection of multiple viral DNAs in disease progression. Ann Surg Oncol. 2015. https://doi.org/10.1245/s10434-015-4888-2. El-shinawi M, Mohamed HT, Abdel-Fattah HH, Ibrahim SAA, El-Halawany MS, Nouh MA, et al. Inflammatory and non-inflammatory breast cancer: a potential role for detection of multiple viral DNAs in disease progression. Ann Surg Oncol. 2015. https://​doi.​org/​10.​1245/​s10434-015-4888-2.
27.
Zurück zum Zitat Yu Y, Morimoto T, Sasa M, Okazaki K, Harada Y, Fujiwara T, et al. Human papillomavirus type 33 DNA in breast cancer in Chinese. Breast Cancer. 2007;7:33–6.CrossRef Yu Y, Morimoto T, Sasa M, Okazaki K, Harada Y, Fujiwara T, et al. Human papillomavirus type 33 DNA in breast cancer in Chinese. Breast Cancer. 2007;7:33–6.CrossRef
28.
Zurück zum Zitat Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, et al. HPV DNA frequency and subset analysis in human breast cancer patients’ normal and tumoral tissue samples. J Exp Clin Cancer Res. 2006;25:515–21.PubMed Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, et al. HPV DNA frequency and subset analysis in human breast cancer patients’ normal and tumoral tissue samples. J Exp Clin Cancer Res. 2006;25:515–21.PubMed
29.
32.
Zurück zum Zitat Hamidi-Fard M, Fattahi-Abdizadeh M, Makvandi M, Ranjbari N, Mansoori E, Samarbaf-Zadeh A. Detection and Genotyping of Human Papillomavirus in Cervical Tissue Samples in Ahvaz, Southwest Iran. Jundishapur J Microbiol. 2013;6(7):e4569. https://doi.org/10.5812/jjm.4569. Hamidi-Fard M, Fattahi-Abdizadeh M, Makvandi M, Ranjbari N, Mansoori E, Samarbaf-Zadeh A. Detection and Genotyping of Human Papillomavirus in Cervical Tissue Samples in Ahvaz, Southwest Iran. Jundishapur J Microbiol. 2013;6(7):e4569. https://​doi.​org/​10.​5812/​jjm.​4569.
33.
Zurück zum Zitat Omire A, Budambula N, Ochieng W, Baliach C, Keros D, Langat H, et al. Assessment of risk predisposition to human papilloma virus through cervical infections screening of women attending an outpatient health facility in Nairobi, Kenya. J Biol Agric Healthcare. 2014;4(22):28–36. Omire A, Budambula N, Ochieng W, Baliach C, Keros D, Langat H, et al. Assessment of risk predisposition to human papilloma virus through cervical infections screening of women attending an outpatient health facility in Nairobi, Kenya. J Biol Agric Healthcare. 2014;4(22):28–36.
38.
Zurück zum Zitat Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15(1):17–35.CrossRefPubMed Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15(1):17–35.CrossRefPubMed
Metadaten
Titel
Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients
verfasst von
Thierry Habyarimana
Mohammed Attaleb
Jean Baptiste Mazarati
Youssef Bakri
Mohammed El Mzibri
Publikationsdatum
19.01.2018
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 2/2018
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-0831-2

Weitere Artikel der Ausgabe 2/2018

Breast Cancer 2/2018 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.